Global Virtual Screening Technology Service Market Strategic Research Report

Scope of the Report

The global Virtual Screening Technology Service market size is predicted to grow from US$ 476 million in 2025 to US$ 1,064 million in 2032; it is expected to grow at a CAGR of 12.3% from 2026 to 2032.

Virtual Screening Technology Service refer to computation-driven technical services used in early-stage molecular discovery, especially in drug discovery, where service providers apply computational chemistry, structural biology, molecular docking, pharmacophore modeling, shape- and fingerprint-based similarity search, QSAR/QSPR, molecular dynamics, free-energy calculations, machine learning, deep learning, generative AI, and high-performance computing to evaluate, rank, and prioritize compounds from real compound collections, purchasable libraries, make-on-demand virtual chemical spaces, or customer-provided molecular datasets.

Based on our research, Virtual Screening Technology Service are evolving from a supporting function within traditional CADD into a more independent, platform-enabled service module in early-stage discovery. The market should not be broadly equated with all CADD software, all AI drug discovery, or all discovery CRO revenue. A more reliable narrow scope focuses on commercially delivered computational screening, compound prioritization, ultra-large chemical-space search, and AI-enabled hit finding. Traditional docking, pharmacophore modeling, shape similarity, and fingerprint-based screening remain the foundation of the field, while AI/ML, active learning, generative molecular design, free-energy rescoring, and automated experimental validation are increasingly integrated into a closed discovery loop. The core value of this service is not to replace experimental screening entirely, but to reduce the number of compounds that need to be synthesized or tested, improve hit quality, and provide more actionable starting points for hit-to-lead and lead optimization.

From the supply side, global providers fall into four major groups. Specialist software and platform vendors such as Schrödinger, Cadence/OpenEye, Cresset, BioSolveIT and Pharmacelera compete on algorithms, cloud workflows and large-scale screening infrastructure. CRO and discovery-service companies such as WuXi AppTec, Pharmaron, Charles River, Sygnature Discovery, Evotec, Selvita, Aurigene and Jubilant Biosys embed virtual screening into broader medicinal chemistry, biology and hit-identification projects. AI drug discovery companies such as XtalPi, Insilico Medicine, DP Technology, StoneWise, HITS, Standigm, Syntekabio and Receptor.AI compete through AI models, proprietary data, generative design and closed-loop discovery capabilities. Compound-library-enabled players such as Enamine, Chemspace, eMolecules, ChemDiv and TargetMol add value by linking virtual libraries to procurement or synthesis. The broad vendor pool is therefore much larger than the core formal list because many related companies sell software, datasets, compounds or compute infrastructure rather than clearly attributable virtual screening services.

Demand is led by pharmaceutical companies, biotech firms, academic translational groups, agrochemical companies, materials discovery teams and AI-enabled discovery platforms. Growth is supported by three structural drivers: the rising need to explore novel and difficult targets, the rapid expansion of synthesizable chemical spaces that cannot be covered economically by wet screening alone, and the availability of AI models, cloud HPC and automated synthesis/testing systems that lower the barrier to large-scale computational screening. In 2025–2026, the fastest growth is expected in ultra-large library screening, AI rescoring, generative hit discovery, CADD-to-biology closed loops, and the commercialization of Chinese and Korean AI discovery platforms. At the same time, simple docking-only services face pricing pressure from open-source tools, standardized workflows and increasing internal capabilities at large pharmaceutical companies.

This report presents a comprehensive overview of the global Virtual Screening Technology Service market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Structure-Based Virtual Screening
• Ligand-Based Virtual Screening
• Others

Segment by Service Model

• One-time Project Services
• Long-term Subscription Services

Segment by Technical Principles

• Structure-Based Virtual Screening (SBVS)
• Ligand-Based Virtual Screening (LBVS)

Segment by Application

• Pharmaceutical Industry
• Biotechnology Industry
• Academic Research Institutions
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Virtual Screening Technology Service market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Pharmaceutical Industry, Biotechnology Industry, Academic Research Institutions evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact